Trending

inflammatory diseases

Holistic immunology: Supporting patients at every stage of their journey

Holistic immunology: Supporting patients at every stage of their journey

As part of our series from leaders at Janssen, the company’s Max Pahlow looks at how approaches to

X

Holistic immunology: Supporting patients at every stage of their journey

https://pharmaphorum.com/r-d/views-analysis-r-d/holistic-immunology-supporting-patients-at-every-stage-of-their-journey/

J&J pays $6.5bn for Momenta and its inflammatory disease hopeful

J&J pays $6.5bn for Momenta and its inflammatory disease hopeful

Johnson & Johnson is to buy Momenta Pharmaceuticals for $6.5 billion, adding potential inflammatory diseases blockbuster nipocalimab to

X

J&J pays $6.5bn for Momenta and its inflammatory disease hopeful

https://pharmaphorum.com/news/jj-pays-6-5bn-for-momenta-and-its-inflammatory-disease-hopeful/

Analysts question Gilead’s commitment to arthritis drug after FDA setback

Analysts question Gilead’s commitment to arthritis drug after FDA setback

The FDA has rejected Gilead and Galapagos’ rheumatoid arthritis (RA) pill filgotinib over concerns that it could damage

X

Analysts question Gilead’s commitment to arthritis drug after FDA setback

https://pharmaphorum.com/news/gilead-could-become/

Roche takes on Alexion as FDA approves satralizumab in NMOSD

Roche takes on Alexion as FDA approves satralizumab in NMOSD

The FDA has approved Roche’s satralizumab for the rare autoimmune disorder Neuromyelitis Optica Spectrum Disorder (NMOSD), under the

X

Roche takes on Alexion as FDA approves satralizumab in NMOSD

https://pharmaphorum.com/news/roche-takes-on-alexion-as-fda-approves-satralizumab-in-nmosd/

Sanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisition

Sanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisition

Sanofi is to buy Principia Biopharma for up to $3.68 billion, adding a potential multiple sclerosis drug to

X

Sanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisition

https://pharmaphorum.com/news/sanofi-adds-btk-inhibitors-to-pipeline-with-3-68bn-principia-biopharma-acquisition/

Kymera Therapeutics begins potential $2bn R&D deal with Sanofi

Kymera Therapeutics begins potential $2bn R&D deal with Sanofi

US biotech Kymera Therapeutics has begun a strategic collaboration with Sanofi to develop and market several drugs tackling immune-inflammatory disease, which

X

Kymera Therapeutics begins potential $2bn R&D deal with Sanofi

https://pharmaphorum.com/news/kymera-therapeutics-begins-potential-2bn-rd-deal-with-sanofi/

Amgen wins latest round in legal tussle over Enbrel patents

Amgen wins latest round in legal tussle over Enbrel patents

Amgen’s reputation as a fearsome adversary in the courtroom remains intact after it won the latest round in

X

Amgen wins latest round in legal tussle over Enbrel patents

https://pharmaphorum.com/news/amgen-wins-latest-round-in-legal-tussle-over-enbrel-patents/

SidekickHealth launches gamified meds management platform with Pfizer

SidekickHealth launches gamified meds management platform with Pfizer

Pfizer and Nordic digital therapeutics firm SidekickHealth have launched a gamified digital medication management and lifestyle platform across Europe in a deal thought to

X

SidekickHealth launches gamified meds management platform with Pfizer

https://pharmaphorum.com/news/sidekickhealth-launches-gamified-meds-management-platform-with-pfizer/

NodThera raises $55m in Series B round to trial inflammatory disease drugs

NodThera raises $55m in Series B round to trial inflammatory disease drugs

The Anglo-US biotech NodThera has raised $55 million in a second financing round as it prepares its inflammatory

X

NodThera raises $55m in Series B round to trial inflammatory disease drugs

https://pharmaphorum.com/news/nodthera-raises/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com